Dopavision
Latest round
- Series A
Last raised
- Apr 2021
Total raised
- $14M
Investors
- 5
About Dopavision
Dopavision GmbH specializes in addressing the progression of myopia using advanced digital therapies. Founded in 2017 and headquartered in Berlin, Germany, the company has engaged in 2 investment deals, with its most recent deal occurring on April 28, 2021.Dopavision’s core offering is MyopiaX®, an innovative digital therapy designed to address the progression of myopia (nearsightedness) in children and adolescents. MyopiaX® combines selective ocular light stimulation with interactive virtual reality experiences to engage young users while delivering therapeutic benefits. By utilizing consumer electronics, MyopiaX® targets specific photosensitive cells in the retina through carefully designed sessions that last several minutes, allowing for seamless integration into daily routines. This non-invasive approach aims to improve eye health outcomes for millions of children globally, with ongoing clinical trials supporting its efficacy and safety. The primary end users are children experiencing myopia, while parents and guardians are integral to the treatment process, overseeing usage to ensure compliance.Dopavision's revenue structure revolves around the MyopiaX® product, which operates on a subscription-based model, ensuring ongoing treatment access for families. Customers, primarily parents of children diagnosed with myopia, engage with the product through direct-to-consumer transactions, facilitated via a user-friendly app that simplifies the therapeutic process. Each subscription may include features such as progress monitoring and access to various interactive games designed to enhance treatment adherence. This model creates a consistent revenue stream and encourages user engagement through regular updates and educational content. The company plans to utilize these funds for additional product development activities and to recruit talent for its development team. Dopavision aims to expand its market presence in Europe, Asia, and North America, targeting regions with high myopia prevalence, and is focused on launching new features for MyopiaX® that enhance user experience and treatment efficacy.
Who invested in Dopavision
5 investors across 1 round
See all investors in Dopavision
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Apr 28, 2021
Amount
$14M
Investors
Questions about Dopavision
Who invested in Dopavision?
Dopavision has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Dopavision raised?
Dopavision has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Dopavision last raise money?
Dopavision's most recent round on record is a Series A, in Apr 2021.
What does Dopavision do?
Dopavision GmbH specializes in addressing the progression of myopia using advanced digital therapies.
Where is Dopavision headquartered?
Dopavision is headquartered in Berlin, Germany.
Which VCs invest in companies like Dopavision?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back medical devices & equipment companies at Dopavision's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series A
Raising like Dopavision? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.